Trial · NCT02342704
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cumulative Number of New T1-Gd+ Lesions | Natalizumab | From Baseline to Week 4 | 0.62 | Standard Deviation 1.512 | lesions |
| Cumulative Number of New T1-Gd+ Lesions | Fingolimod | From Baseline to Week 4 | 1.69 | Standard Deviation 4.122 | lesions |
| Cumulative Number of New T1-Gd+ Lesions | Natalizumab | From Baseline to Week 12 | 0.68 | Standard Deviation 1.695 | lesions |
| Cumulative Number of New T1-Gd+ Lesions | Fingolimod | From Baseline to Week 12 | 2.27 | Standard Deviation 4.499 | lesions |
| Cumulative Number of New T1-Gd+ Lesions | Natalizumab | From Baseline to Week 24 | 0.72 | Standard Deviation 1.69 | lesions |
| Cumulative Number of New T1-Gd+ Lesions | Fingolimod | From Baseline to Week 24 | 2.6 | Standard Deviation 4.745 | lesions |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24 | Natalizumab | T1 Lesion Volume Change | 0.5 | Standard Deviation 31.235 | percentage change |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24 | Fingolimod | T1 Lesion Volume Change | 1.81 | Standard Deviation 19.703 | percentage change |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24 | Natalizumab | T2 Lesion Volume Change | 0.08 | Standard Deviation 4.399 | percentage change |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24 | Fingolimod | T2 Lesion Volume Change | 3.32 | Standard Deviation 5.036 | percentage change |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52 | Fingolimod | T1 Lesion Volume Change | -15.31 | Standard Deviation NA | percentage change |
| Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52 | Fingolimod | T2 Lesion Volume Change | 5.6 | Standard Deviation NA | percentage change |
| Cumulative Number of New or Enlarging T2 Lesions | Natalizumab | 1.33 | Standard Deviation 2.469 | lesions | |
| Cumulative Number of New or Enlarging T2 Lesions | Fingolimod | 1.94 | Standard Deviation 2.205 | lesions | |
| Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24 | Natalizumab | 3.79 | Standard Deviation 8.684 | units on a scale | |
| Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24 | Fingolimod | 3.24 | Standard Deviation 4.63 | units on a scale | |
| Change From Baseline in SDMT at Week 52 | Fingolimod | 2.11 | Standard Deviation 8.492 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02342704/results